ExoticRx · exoticrx.com/drugs/surovetmab
Surovetmab
Stelfonta Adjunct
Drug Class
Routes
Indications
Mechanism of Action
Anti-PD-L1 canine monoclonal antibody checkpoint inhibitor. Blocks PD-1/PD-L1 interaction to restore T-cell mediated anti-tumor immune response.
Side effects & warnings
Investigational/conditionally approved. Immune-mediated adverse events possible. Monitor for autoimmune-like reactions. Dogs only.
Species with Surovetmab dosing data (1 dose rule)
Evidence levels across 1 dose rule
Each ExoticRx dose rule is graded by the strength of its primary evidence — see the editorial process.
Backed by a published primary source
- · Papich Handbook of Veterinary Drugs, 5th Ed
Sample dosing (1 of 1 cited rule)
Free-tier preview — dog and cat dosing. Pro and Student unlock all 1 species including reptiles, birds, pocket pets, livestock, and equine.
| Species | Route | Dose | Frequency | Evidence | Source |
|---|---|---|---|---|---|
| Dog (Domestic) | IV | 5–10 mg/kg | q2-3 weeks | Weak | Papich Handbook of Veterinary Drugs, 5th Ed |
Upgrade for Full Details
Upgrade to Pro or Student to access full drug details including mechanism of action, warnings, dose ranges, and frequency.
View PlansMore Vaccine/Biologic drugs
Source citations and evidence levels available on the live page. Reference only — verify against current literature before clinical use.